Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

130 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Integrated Analysis of the RASH Study with the Use of the "Burden of Therapy" (BOTh®TM) Methodology-A Novel Tool for Assessing Adverse Events in Metastatic Pancreatic Cancer.
Dorman K, Boeck S, Snijder RJ, Siveke JT, Schenk M, Mayerle J, Caca K, Freiberg-Richter J, Fischer von Weikersthal L, Kullmann F, Reinacher-Schick A, Fuchs M, Kanzler S, Kunzmann V, Ettrich TJ, Zhang D, Held S, Abdul-Ahad A, von Bergwelt-Baildon M, Heinemann V, Haas M. Dorman K, et al. Among authors: kanzler s. Curr Oncol. 2023 Jun 17;30(6):5828-5834. doi: 10.3390/curroncol30060436. Curr Oncol. 2023. PMID: 37366919 Free PMC article.
Adjuvant Treatment with S-1 in Patients after R0-Resection of Adenocarcinoma of the Stomach and Esophagogastric Junction: A Multicenter Phase I/II Feasibility Study (GMBH-STO-0114).
Heinrich K, Heinemann V, Stintzing S, Müller L, Ettrich TJ, Büchner-Steudel P, Geißler M, Trojan J, Moosmann N, Folprecht G, Schmidt J, Kanzler S, Kullmann F, Moulin JC, Werner J, Angele MK, Probst V, Held S, Schulz C, Boukovala M. Heinrich K, et al. Among authors: kanzler s. Oncol Res Treat. 2024;47(6):251-261. doi: 10.1159/000538143. Epub 2024 Apr 2. Oncol Res Treat. 2024. PMID: 38565089 Free PMC article. Clinical Trial.
Nanoliposomal irinotecan and fluorouracil plus leucovorin versus fluorouracil plus leucovorin in patients with cholangiocarcinoma and gallbladder carcinoma previously treated with gemcitabine-based therapies (AIO NALIRICC): a multicentre, open-label, randomised, phase 2 trial.
Vogel A, Saborowski A, Wenzel P, Wege H, Folprecht G, Kretzschmar A, Schütt P, Jacobasch L, Ziegenhagen N, Boeck S, Zhang D, Kanzler S, Belle S, Mohm J, Gökkurt E, Lerchenmüller C, Graeven U, Pink D, Götze T, Kirstein MM. Vogel A, et al. Among authors: kanzler s. Lancet Gastroenterol Hepatol. 2024 Aug;9(8):734-744. doi: 10.1016/S2468-1253(24)00119-5. Epub 2024 Jun 10. Lancet Gastroenterol Hepatol. 2024. PMID: 38870977 Free article. Clinical Trial.
Alternating gemcitabine plus nab-paclitaxel and gemcitabine alone versus continuous gemcitabine plus nab-paclitaxel after induction treatment of metastatic pancreatic cancer (ALPACA): a multicentre, randomised, open-label, phase 2 trial.
Dorman K, Boeck S, Caca K, Reichert M, Ettrich TJ, Oettle H, Waidmann O, Modest DP, Müller L, Michl P, Kanzler S, Pink D, Reinacher-Schick A, Geißler M, Pelz H, Kunzmann V, Held S, Schichtl T, Heinemann V, Kullmann F. Dorman K, et al. Among authors: kanzler s. Lancet Gastroenterol Hepatol. 2024 Oct;9(10):935-943. doi: 10.1016/S2468-1253(24)00197-3. Epub 2024 Aug 16. Lancet Gastroenterol Hepatol. 2024. PMID: 39159648 Clinical Trial.
Paclitaxel/Ramucirumab versus Paclitaxel in 2nd-Line Therapy of Advanced Esophageal Squamous Cell Carcinoma: Randomized Phase II IKF-AIO-RAMOS Trial.
Scheck MK, Goetze TO, Ettrich TJ, Schmalenberg H, Clemens M, Mahlberg R, Heeg S, Kanzler S, Hapke G, Thuss-Patience P, Kestler A, Treschl A, Heidel S, Schiemer M, Sookthai D, Junge S, Pauligk C, Al-Batran SE, Lorenzen S. Scheck MK, et al. Among authors: kanzler s. Oncol Res Treat. 2024;47(11):549-560. doi: 10.1159/000541174. Epub 2024 Sep 9. Oncol Res Treat. 2024. PMID: 39250905 Clinical Trial.
Efficacy and quality of life for FOLFOX/bevacizumab +/- irinotecan in first-line metastatic colorectal cancer-final results of the AIO CHARTA trial.
Schmoll HJ, Mann J, Meinert F, Garlipp B, Borchert K, Vogel A, Goekkurt E, Kaiser U, Hoeffkes HG, Rüssel J, Kanzler S, Edelmann T, Forstbauer H, Göhler T, Hannig C, Hildebrandt B, Roll C, Bokemeyer C, Steighardt J, Cygon F, Ibach S, Stein A, Tintelnot J. Schmoll HJ, et al. Among authors: kanzler s. Br J Cancer. 2024 Feb;130(2):233-241. doi: 10.1038/s41416-023-02496-4. Epub 2023 Nov 23. Br J Cancer. 2024. PMID: 37996507 Free PMC article.
Rare HCV subtypes and retreatment outcomes in a cohort of European DAA-experienced patients.
Dietz J, Graf C, Berg CP, Port K, Deterding K, Buggisch P, Peiffer KH, Vermehren J, Dultz G, Geier A, Reiter FP, Bruns T, Schattenberg JM, Durmashkina E, Gustot T, Moreno C, Trauth J, Discher T, Fischer J, Berg T, Kremer AE, Müllhaupt B, Zeuzem S, Sarrazin C; European HCV Resistance Study Group. Dietz J, et al. JHEP Rep. 2024 Mar 25;6(7):101072. doi: 10.1016/j.jhepr.2024.101072. eCollection 2024 Jul. JHEP Rep. 2024. PMID: 39006503 Free PMC article.
Long-term persistence of HCV resistance-associated substitutions after DAA treatment failure.
Dietz J, Müllhaupt B, Buggisch P, Graf C, Peiffer KH, Matschenz K, Schattenberg JM, Antoni C, Mauss S, Niederau C, Discher T, Trauth J, Dultz G, Schulze Zur Wiesch J, Piecha F, Klinker H, Müller T, Berg T, Neumann-Haefelin C, Berg CP, Zeuzem S, Sarrazin C; German HCV Resistance Study Group; University Hospitals; Academic Hospitals; Local study sites (private practices), Germany. Dietz J, et al. J Hepatol. 2023 Jan;78(1):57-66. doi: 10.1016/j.jhep.2022.08.016. Epub 2022 Aug 27. J Hepatol. 2023. PMID: 36031158
Efficacy and Safety of ELOM-080 as Add-On Therapy in COVID-19 Patients with Acute Respiratory Insufficiency: Exploratory Data from the Prospective Placebo-Controlled COVARI Trial.
Dreher M, Grohè C, Hartmann NU, Kanzler S, Kraft K, Sarrazin C, Doll M, Spiesshöfer J, Steiner S, Wöhrle J, Seeger J, Röschmann-Doose K, Thomsen J, Wittig T, Marx N, Eisenmann S. Dreher M, et al. Among authors: kanzler s. Adv Ther. 2022 Jun;39(6):3011-3018. doi: 10.1007/s12325-022-02135-z. Epub 2022 Apr 13. Adv Ther. 2022. PMID: 35419650 Free PMC article. Clinical Trial.
130 results